Three burning 2024 questions for Pfizer: What to do in weight loss, the hunt for megablockbusters, and integrating the deals

Pfiz­er has de­clared 2024 to be a year of ex­e­cu­tion. It’s like­ly to be judged on whether it can al­so be a year when the stock turned around, and in­vestors turned in­to be­liev­ers of its post-Covid strat­e­gy.

On Tues­day, the com­pa­ny an­nounced fi­nan­cial re­sults for the fi­nal quar­ter of 2023. It’s em­braced cost cuts, im­proved the bal­ance sheet and in­te­grat­ed the com­pa­nies they ac­quired us­ing the prof­its that were gen­er­at­ed through their (now in de­cline) Covid prod­ucts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.